Nothing Special   »   [go: up one dir, main page]

BR112014017780A8 - Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos - Google Patents

Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos

Info

Publication number
BR112014017780A8
BR112014017780A8 BR112014017780A BR112014017780A BR112014017780A8 BR 112014017780 A8 BR112014017780 A8 BR 112014017780A8 BR 112014017780 A BR112014017780 A BR 112014017780A BR 112014017780 A BR112014017780 A BR 112014017780A BR 112014017780 A8 BR112014017780 A8 BR 112014017780A8
Authority
BR
Brazil
Prior art keywords
compounds
tricyclic
methods
making
sulphone compounds
Prior art date
Application number
BR112014017780A
Other languages
English (en)
Other versions
BR112014017780A2 (pt
Inventor
Mary Cramp Susan
David Pallin Thomas
Joan Dyke Hazel
Zahler Robert
Original Assignee
Zafgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zafgen Inc filed Critical Zafgen Inc
Publication of BR112014017780A2 publication Critical patent/BR112014017780A2/pt
Publication of BR112014017780A8 publication Critical patent/BR112014017780A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOSTOS DE SULFONA TRICÍCLICOS, COMPOSIÇÃO FARMACEUTICAMENTE ACEITÁVEL E USO DOS DITOS COMPOSTOS. A invenção fornece compostos de sulfona tricíclicos e sua utilização no tratamento de distúrbios médicos, tal como obesidade. Composições farmacêuticas e métodos para fazer vários compostos tricíclicos são fornecidos. Os compostos são contemplados para ter atividade contra metionil aminopeptidase 2.
BR112014017780A 2012-01-18 2013-01-17 Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos BR112014017780A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261587825P 2012-01-18 2012-01-18
PCT/US2013/021914 WO2013109735A1 (en) 2012-01-18 2013-01-17 Tricyclic sulfone compounds and methods of making and using same

Publications (2)

Publication Number Publication Date
BR112014017780A2 BR112014017780A2 (pt) 2017-06-20
BR112014017780A8 true BR112014017780A8 (pt) 2017-07-11

Family

ID=47710307

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014017780A BR112014017780A8 (pt) 2012-01-18 2013-01-17 Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos

Country Status (10)

Country Link
US (1) US9440943B2 (pt)
EP (1) EP2804856B1 (pt)
JP (1) JP2015509102A (pt)
KR (1) KR20140112566A (pt)
CN (1) CN104169268A (pt)
AU (1) AU2013209719A1 (pt)
BR (1) BR112014017780A8 (pt)
CA (1) CA2861381A1 (pt)
MX (1) MX2014008705A (pt)
WO (1) WO2013109735A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
EA025526B1 (ru) * 2011-05-06 2017-01-30 Зафджен Инк. Частично насыщенные трициклические соединения и способы их получения и применения
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
KR20140112565A (ko) 2012-01-18 2014-09-23 자프겐 인크. 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
US9839622B2 (en) 2012-05-08 2017-12-12 Zafgen, Inc. Methods of treating hypothalamic obesity
US9573918B2 (en) 2012-05-09 2017-02-21 Zafgen, Inc. Fumigillol compounds and methods of making and using same
CN104918615B (zh) 2012-11-05 2018-10-12 扎夫根股份有限公司 治疗肝病的方法
BR112015010223A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
AU2013337282A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds and methods of making and using same
JP2016513722A (ja) 2013-03-14 2016-05-16 ザフゲン，インコーポレイテッド 腎臓病及び他の疾患の治療方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
SI3390355T1 (sl) * 2016-03-22 2023-07-31 Helsinn Healthcare S. A. Benzensulfonil-asimetrične sečnine in njihove medicinske uporabe
CN107056742A (zh) * 2017-04-20 2017-08-18 牛永友 一种治疗哮喘的药物组合物
CN112898202B (zh) * 2021-01-27 2022-11-22 中国科学院上海有机化学研究所 一种杂环基并环丙烷化合物、合成方法

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164410A (en) 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
PH26256A (en) 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
ES2099064T3 (es) 1988-09-01 1997-05-16 Takeda Chemical Industries Ltd Derivados de fumagillol.
US5180738A (en) 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
ATE87623T1 (de) 1989-03-06 1993-04-15 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
US5288722A (en) 1989-03-06 1994-02-22 Takeda Chemical Industries, Ltd. 6-amino-6-desoxyfumagillols, production and use thereof
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
US6017954A (en) 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
EP0415294A3 (en) 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (pt) 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
DE69330690T2 (de) 1992-01-30 2002-06-20 Takeda Chemical Industries, Ltd. Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe
ATE153854T1 (de) 1992-12-16 1997-06-15 Takeda Chemical Industries Ltd Stabile pharmazeutische zubereitung mit fumagillolderivaten
DE69600879T2 (de) 1995-03-27 1999-06-02 Assistance Publique, Hopitaux De Paris, Paris Verwendung von fumagillol und seinen derivaten zur herstellung von arzneimitteln gegen darminfektionen
US6180626B1 (en) 1995-10-11 2001-01-30 Fujisawa Pharmaceutical Co., Ltd. Vascular-permeability suppressants
EP0799616A1 (en) 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
WO1998005293A2 (en) 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US6281245B1 (en) 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
IL131494A (en) 1997-03-04 2005-06-19 Monsanto Co N-hydroxy 4-sulfonyl butanamide compounds and their use to prepare medicaments for treating conditions associated with matrix metalloproteinase activity
WO1998056372A1 (en) 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
ATE269699T1 (de) 1997-10-31 2004-07-15 Childrens Medical Center Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe
BR9814327A (pt) 1997-12-23 2000-10-03 Warner Lambert Co Compostos de tiouréia e benzamida, composições e pro-cessos para tratamento ou prevenção de doenças infla-matórias e arteriosclerose
US6242494B1 (en) 1998-05-01 2001-06-05 Abbott Laboratories Substituted β-amino acid inhibitors of methionine aminopeptidase-2
KR100357541B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
JP2000116337A (ja) 1998-10-09 2000-04-25 Nippon Shokuhin Kako Co Ltd ペットフード
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2000064876A1 (en) 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands
JP3779615B2 (ja) 1999-07-15 2006-05-31 ビーエーエスエフ アクチェンゲゼルシャフト ５−および／または６−置換−２−ヒドロキシ安息香酸エステルの製造方法
WO2001024796A1 (en) 1999-10-01 2001-04-12 Smithkline Beecham Corporation 1,2,4-triazole derivatives, composition, process of making and methods of use
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
US6323228B1 (en) 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
UY26929A1 (es) 2000-09-29 2002-04-26 Abbott Lab Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
CA2426703C (en) 2000-11-01 2005-09-13 Praecis Pharmaceuticals Incorporated Therapeutic agents and methods of use thereof for the modulation of angiogenesis
SK7032003A3 (en) 2000-12-20 2004-04-06 Bristol Myers Squibb Co Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
JP2004525942A (ja) 2001-03-29 2004-08-26 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US20020183242A1 (en) 2001-04-11 2002-12-05 Jack Henkin Peptide antiangiogenic drugs
WO2003027104A1 (en) 2001-09-27 2003-04-03 Idrtech Inc. Fumagillol derivatives and preparing method thereof
US6803382B2 (en) 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US6989392B2 (en) 2002-06-18 2006-01-24 Abbott Laboratories 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20040067266A1 (en) 2002-10-07 2004-04-08 Toppo Frank R. Weight loss compound
US20040068012A1 (en) 2002-10-08 2004-04-08 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US20040157836A1 (en) 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
WO2005016897A1 (en) 2003-08-08 2005-02-24 Janssen Pharmaceutica, N.V. Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds
AR046330A1 (es) 2003-09-09 2005-12-07 Japan Tobacco Inc Inhibidor de dipeptidilpeptidasa iv
AU2004309367B2 (en) 2003-12-22 2010-04-01 Memory Pharmaceuticals Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
EP1699812A2 (en) 2003-12-29 2006-09-13 Praecis Pharmaceuticals Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof
KR100552043B1 (ko) 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
US7932252B2 (en) 2004-05-12 2011-04-26 Chemocentryx, Inc. Aryl sulfonamides
WO2006004803A1 (en) 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
AU2005289887A1 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Sulfonamide compounds
JP2008528574A (ja) 2005-01-26 2008-07-31 チョン クン ダン ファーマシューティカル コープ． フマギロール誘導体またはフマギロール誘導体の製造方法およびこれを含む医薬用組成物
FR2886855B1 (fr) 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
US20070078172A1 (en) 2005-06-16 2007-04-05 Jenrin Discovery Mao-b inhibitors useful for treating obesity
US7282588B2 (en) 2005-12-23 2007-10-16 Smithkline Beecham Azaindole inhibitors of aurora kinases
WO2008008374A2 (en) 2006-07-14 2008-01-17 Chemocentryx, Inc. Ccr2 inhibitors and methods of use thereof
DE102007020492A1 (de) 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Sulfonamid-Derivate
WO2009003110A2 (en) 2007-06-26 2008-12-31 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
JP5557746B2 (ja) 2007-11-28 2014-07-23 メルサナ セラピューティックス，インク． 生体適合性生分解性フマギリンアナログ複合体
PT2227466E (pt) 2007-11-30 2011-07-01 Bayer Schering Pharma Ag Piperidinas com substituição heteroarilo
AU2009270799B2 (en) 2008-07-18 2016-05-19 Zafgen, Inc. Methods of treating an overweight or obese subject
ES2641471T3 (es) 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
WO2010048499A1 (en) 2008-10-24 2010-04-29 Wake Forest University Platinum acridine anti-cancer compounds and methods thereof
WO2010065883A2 (en) * 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
WO2010065881A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
US20120010290A1 (en) 2008-12-04 2012-01-12 Vath James E Methods of Treating an Overweight or Obese Subject
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
CN102639494B (zh) * 2009-10-09 2016-11-09 扎夫根公司 砜化合物及其制备和使用方法
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
US20130023513A1 (en) 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
US20130210821A1 (en) 2010-05-27 2013-08-15 James E. Vath Methods for Treating Obesity
US20120020647A1 (en) 2010-07-21 2012-01-26 Rovi Technologies Corporation Filtering repeated content
CA2806221A1 (en) 2010-07-22 2012-01-26 Zafgen, Inc. Tricyclic compounds and methods of making and using same
US8428080B2 (en) 2010-09-16 2013-04-23 Apple Inc. Method to control reconfiguration of multiple radio access bearers in a wireless device
AU2011316550A1 (en) 2010-10-12 2013-05-02 Zafgen, Inc Sulphonamide compounds and methods of making and using same
MY177039A (en) 2010-11-09 2020-09-03 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
CA2825408A1 (en) 2011-01-26 2012-08-02 Zafgen, Inc. Tetrazole compounds and methods of making and using same
MX343687B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
EA025526B1 (ru) 2011-05-06 2017-01-30 Зафджен Инк. Частично насыщенные трициклические соединения и способы их получения и применения
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
WO2013033430A1 (en) 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
BR112015010223A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
AU2013337282A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds and methods of making and using same

Also Published As

Publication number Publication date
WO2013109735A1 (en) 2013-07-25
EP2804856A1 (en) 2014-11-26
US20150119456A1 (en) 2015-04-30
CN104169268A (zh) 2014-11-26
KR20140112566A (ko) 2014-09-23
JP2015509102A (ja) 2015-03-26
CA2861381A1 (en) 2013-07-25
BR112014017780A2 (pt) 2017-06-20
EP2804856B1 (en) 2017-03-15
US9440943B2 (en) 2016-09-13
AU2013209719A1 (en) 2014-08-07
MX2014008705A (es) 2015-02-05

Similar Documents

Publication Publication Date Title
BR112014017780A8 (pt) Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos
BR112013028665A2 (pt) compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
BR112013001613A2 (pt) compostos tricíclicos e métodos para fazer e usar os mesmos.
BR112014017673A8 (pt) Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
MX339201B (es) Compuestos de sulfonamida y métodos para elaborarlos y usarlos.
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
PH12017501306A1 (en) Inhibitors of histone demethylases
BR112014016165A2 (pt) compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
BR112012016797A2 (pt) intensificador dinâmico de baixo utilizando compressor com equalizador incorporado
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
ES2446643R1 (es) Composiciones farmacéuticas combinadas y su uso para preparar un medicamento destinado al tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
EA201890532A1 (ru) Новые аннелированные бензамиды
BR112015013675A2 (pt) composições compreendendo vortioxetina e donepezil
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]